Cargando…

The European Medicines Agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients

Detalles Bibliográficos
Autores principales:	DeVries, J Hans, Irs, Alar, Hillege, Hans L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	CardioPulse
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542624/ https://www.ncbi.nlm.nih.gov/pubmed/37482673 http://dx.doi.org/10.1093/eurheartj/ehad429

Ejemplares similares

The ESC Working Group on cardiovascular regenerative and reparative medicine
por: Pompilio, Giulio, et al.
Publicado: (2023)

Medical Misinformation: Vet the Message!
por: Hill, Joseph A, et al.
Publicado: (2019)

The PROFID project
por: Dagres, Nikolaos, et al.
Publicado: (2020)

Heart Team meetings during COVID-19: Different formats of multidisciplinary Heart Team meetings under the gathering restriction rules due to the coronavirus disease-2019 pandemic are discussed
por: Wahadat, Ali R, et al.
Publicado: (2020)

COVID-19 and Katrina: recalcitrant racial disparities
por: Van Spall, Harriette G C, et al.
Publicado: (2020)

Cardiovascular guidelines based on high-quality evidence: Are we getting there?
por: van Dijk, Wouter B, et al.
Publicado: (2019)

The impossible interviews—Sherlock Holmes interviews David Sackett: ‘how much can we trust the guidelines?’
por: Rapezzi, Claudio, et al.
Publicado: (2021)

Putting (One's) Heart into Music
por: Chew, Elaine, et al.
Publicado: (2021)

Antithrombotic therapy in patients undergoing transcatheter aortic valve replacement
por: Han, Yaling
Publicado: (2022)

Providing next-generation haemodynamic risk prediction through multiscale imaging of cardiovascular pressure gradients: the Horizon Europe MultiPRESS project
por: Marlevi, David
Publicado: (2023)

Rediscovery of magnetocardiography for diagnostic screening and monitoring of treatment response in cardiology
por: Heidecker, Bettina
Publicado: (2023)

Targeting non-coding RNAs for novel treatment strategies in vascular diseases
por: Winter, Hanna, et al.
Publicado: (2023)

Are we ready for cell-specific therapies in atherosclerosis?
por: Khan, Abdul Waheed
Publicado: (2023)

Somatic mutations in vascular wall function and age-associated disease
por: Revêchon, Gwladys, et al.
Publicado: (2023)

Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions
por: Dong, Tiffany, et al.
Publicado: (2023)

Alcohol Septal Ablation or Mavacamten for Obstructive Hypertrophic Cardiomyopathy
por: Scholtz, Smita, et al.
Publicado: (2023)

Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial
por: Tian, Zhuang, et al.
Publicado: (2023)

Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy and the impact of mavacamten
por: Mathai, Susan, et al.
Publicado: (2022)

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy
por: Braunwald, Eugene, et al.
Publicado: (2023)

A call to embrace a culture of openness in cardiovascular research
por: Cobey, Kelly D, et al.
Publicado: (2022)

Smart cardiac magnetic resonance delivering one-click and comprehensive assessment of cardiovascular disease
por: Bustin, Aurelien, et al.
Publicado: (2023)

CureHeart wins Big Beat Challenge, a £30 million research award from the British Heart Foundation( )
por: Avkiran, Metin
Publicado: (2022)

Using routinely collected health record data for the earlier detection of heart failure with preserved ejection fraction: FIND-HFpEF
por: Nadarajah, Ramesh, et al.
Publicado: (2023)

Rare association of left ventricular non-compaction and hypertrophic cardiomyopathy
por: Hotta, Viviane Tiemi, et al.
Publicado: (2020)

The Impact of Mavacamten on the Pathophysiology of Hypertrophic Cardiomyopathy: A Narrative Review
por: Edelberg, Jay M., et al.
Publicado: (2022)

European Society of Cardiology and Radical Health Festival Helsinki join forces to transform healthcare as we know it
por: Hindricks, Gerhard
Publicado: (2023)

Considerations for managed care pharmacy in evaluating mavacamten, a novel agent for obstructive hypertrophic cardiomyopathy
por: Taddei-Allen, Patty
Publicado: (2022)

Concerns with Patient Reported Outcome Measurement and Value Claims for Therapy Response: The Case of Mavacamten and Symptomatic Hypertrophic Cardiomyopathy (SHCM)
por: Langley, Paul C
Publicado: (2022)

Efficacy and safety of mavacamten in treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis
por: Memon, Areeba, et al.
Publicado: (2023)

What is linking COVID-19 and endothelial dysfunction? Updates on nanomedicine and bioengineering from the 2020 AHA Scientific Sessions
por: Gambardella, Jessica, et al.
Publicado: (2020)

The U‐shape relationship between pulse pressure level on inpatient admission and long‐term mortality in acute coronary syndrome patients undergoing percutaneous coronary intervention
por: Wei, Huang, et al.
Publicado: (2021)

Influencing factors of wide pulse pressure in an elderly Chinese population: A cross‐sectional study
por: Yang, Dandan, et al.
Publicado: (2022)

Meet Key Digital Health thought Leaders: Gerhard Hindricks
por: Bruining, Nico
Publicado: (2022)

Meet key Digital Health thought leaders
por: Nico, Bruining
Publicado: (2021)

The Mayo Clinic: digital health centre of excellence
por: Bruining, Nico, et al.
Publicado: (2022)

Meet key digital health thought leaders: Hugo Saner
por: Bruining, Nico
Publicado: (2022)

Meet key Digital Health thought leaders
por: Bruining, Nico
Publicado: (2021)

Meet key Digital Health thought leaders: Benjamin Meder
por: van der Boon, Robert M A
Publicado: (2022)

Meet key digital health thought leaders: David Albert
por: Bruining, Nico
Publicado: (2023)

The 2022 European Society of Cardiology Cardio-oncology Guidelines in Focus
por: Gent, David G, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mu81aerlkd2d349s7v40j04pbv